Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2026-01-04 @ 2:06 AM
Study NCT ID:
NCT05286957
Status:
RECRUITING
Last Update Posted:
2023-03-17
First Post:
2022-03-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
L2021-Y471
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |